Acurx Pharmaceuticals, Inc. Quarterly report [Sections 13 or 15(d)]

ACCOUNTS PAYABLE AND ACCRUED EXPENSES

9 Months Ended

Sep. 30, 2026

NOTE 3 – ACCOUNTS PAYABLE AND ACCRUED EXPENSES

Accounts payable and accrued expenses as of September 30, 2026 and December 31, 2025 were as follows:


		September 30, 2026			December 31, 2025
Accrued research and development		$	2,612,231		$	2,311,348
Accrued compensation expenses			295,422			39,011
Accrued professional fees			75,287			63,782
Other accounts payable and accrued expenses			10,298			6,802
Total		$	2,993,238		$	2,420,943